Boehringer Ingelheim, AbbVie deal

AbbVie and Boehringer partnered to develop and commercialize Boehringer’s BI 655066 and BI 655064. Boehringer will receive $595 million up front and is eligible for undisclosed milestones plus royalties.

Both partners will be responsible for developing BI 655066 for an initial period. Boehringer will conduct Phase III trials for psoriasis before transitioning responsibility to AbbVie. AbbVie will be responsible for worldwide commercialization, and Boehringer will have the option to co-promote the compound for asthma. ...